Yüksel ALTUNTAŞ, Okcan BASAT, Emine ŞATIR, Sema UÇAK

Compliance to treatment and reaching of metabolic goals are better in OAD-treated diabetics than insulin-treated diabetics in the Turkish population

We assessed the success rates of reaching glycated haemoglobin (HbA1c) goals in different treatment groups. Materials and methods: This was a single-centre, retrospective study including 2995 patients. The proportion of patients reaching their HbA1c goals, according to the International Diabetes Federation (IDF), American Association of Clinical Endocrinologists (AACE), and American Diabetes Association (ADA), were determined. Results: There were 4 different treatment groups: 1) diet group (n = 140), 2) oral antidiabetic drug (OAD) group (n = 1238), 3) insulin group (n = 765), and 4) insulin + OAD group (n = 812). According to the IDF and AACE criteria, the proportion of patients reaching HbA1c levels of ≤6.5% was 92% in group 1, and 1 year later it was 100%. In the OAD group the proportions were 61% and 69%, respectively. In the insulin group, the rate was 15% and 1 year later 33% of patients had reached their goals. In the insulin + OAD group, the rates were 10% and 21%, respectively (P < 0.05 for all). According to the ADA criteria, the rate of patients reaching HbA1c levels of =

Anahtar Kelimeler:

Key words: HbA1c goals, oral antidiabetic drugs, insulin

Compliance to treatment and reaching of metabolic goals are better in OAD-treated diabetics than insulin-treated diabetics in the Turkish population

Keywords:

Key words: HbA1c goals, oral antidiabetic drugs, insulin,

PDF

___

American Diabetes Association. Standards of Medical Care in Diabetes 2008 Position Statements [Position Statement]. Diabetes Care 2008; 31: S12–54.
Cooppan R. General approach to the treatment of diabetes mellitus. In: Kahn CR, Weir G, King G, Jacobson A, Smith R, Moses A, editors. Joslin’s diabetes mellitus. 14 th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p.587–96.
Liebl A, Mata M, Eschwège E. Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia 2002; 45: 23–8.
Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335–42.
Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 1999; 22: 403–8.
Chuang LM, Tsai ST, Huang BY, Tai TY. DiabCare-Asia 1998 Study Group. The status of diabetes control in Asia – a crosssectional survey of 24 317 patients with diabetes mellitus in 19 Diabet Med 2002; 19: 978–85.
O’Hare JP, Raymond NT, Mughal S, Dodd L, Hanif W, Ahmed Y et al. on behalf of the UKADS study group. Evaluation of delivery of enhanced diabetes care for patients of South Asian ethnicity: the United Kingdom Asian Diabetes Study (UKADS). Diabet Med 2004; 21: 1357–65.
Ekström N, Miftaraj M, Svensson AM, Andersson Sundell K, Cederholm J, Zethelius B et al. Glucose-lowering treatment and clinical results in 163 121 patients with type 2 diabetes: an observational study from the Swedish national diabetes register. Diabetes Obes Metab 2012; 14: 717–26.
Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963–72.
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009; 32: 193–203.
American Association of Clinical Endocrinologists. State of Diabetes in America, 2003–2004. Jacksonville, Florida: American Association of Clinical Endocrinologists; 2003– 200 Available at http://www.nbch.org/CHVC/toolkit/ DiabetesAmericaReport.pdf, accessed 1 June 2009.
Polonsky WH. Understanding and assessing diabetes-specific quality of life. Diabetes Spectrum 2000; 13: 36–41.
Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB et al. Effects of intensive glucose lowering in type 2 diabetes. Action to Control Cardiovascular Risk in Diabetes Study Group. N Engl J Med 2008; 358: 2545–59.
Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–72.
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405–12.
Ökten A, Kaya G, Karagüzel G, Gedik Y, Aslan Y. Limited joint mobility in 77 children with type i diabetes mellitus and correlation to other diabetic complications. Turk J Med Sci 2012; 42: 523–31.
Azal Ö, Özkardes A, Önde ME, Özata M, Özışık G, Çorakçı A et al. Visual evoked potentials in diabetic patients. Turk J Med Sci 1998; 28: 533–6.
Atamer Y, Koçyiğit Y, Atamer A, Mete N, Canoruç N, Toprak G. Alterations of erythrocyte and plasma lipid peroxides as well as antioxidant mechanism in patients with type II diabetes mellitus (NIDDM). Turk J Med Sci 1998; 28: 139–42.